190 related articles for article (PubMed ID: 29199359)
1. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
[TBL] [Abstract][Full Text] [Related]
2. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
[TBL] [Abstract][Full Text] [Related]
3. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
4. Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Álvarez-Gutiérrez A; Montero-Corominas D
Bone; 2017 Dec; 105():292-298. PubMed ID: 28890137
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Khalid S; Calderon-Larranaga S; Sami A; Hawley S; Judge A; Arden N; Van Staa TP; Cooper C; Abrahamsen B; Javaid MK; Prieto-Alhambra D
Osteoporos Int; 2022 Jul; 33(7):1579-1589. PubMed ID: 35138412
[TBL] [Abstract][Full Text] [Related]
6. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Breart G; Cooper C; Meyer O; Speirs C; Deltour N; Reginster JY
Osteoporos Int; 2010 Jul; 21(7):1181-7. PubMed ID: 19806285
[TBL] [Abstract][Full Text] [Related]
8. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
10. The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study.
Martín-Merino E; Calderón-Larrañaga A; Hawley S; Poblador-Plou B; Llorente-García A; Petersen I; Prieto-Alhambra D
Clin Epidemiol; 2018; 10():643-654. PubMed ID: 29892204
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
[TBL] [Abstract][Full Text] [Related]
12. Drug-Related Adverse Events of Osteoporosis Therapy.
Khan M; Cheung AM; Khan AA
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
[TBL] [Abstract][Full Text] [Related]
13. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance.
Ali MS; Berencsi K; Marinier K; Deltour N; Perez-Guthann S; Pedersen L; Rijnbeek P; Lapi F; Simonetti M; Reyes C; Van der Lei J; Sturkenboom M; Prieto-Alhambra D
Osteoporos Int; 2020 Dec; 31(12):2425-2438. PubMed ID: 32757044
[TBL] [Abstract][Full Text] [Related]
15. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
[TBL] [Abstract][Full Text] [Related]
16. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Svanström H; Pasternak B; Hviid A
Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
[TBL] [Abstract][Full Text] [Related]
17. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
18. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
Cooper C; Fox KM; Borer JS
Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
20. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
